Opendata, web and dolomites

IMMUNOSABR SIGNED

Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "IMMUNOSABR" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT MAASTRICHT 

Organization address
address: Minderbroedersberg 4-6
city: MAASTRICHT
postcode: 6200 MD
website: http://www.maastrichtuniversity.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.immunosabr.info/
 Total cost 5˙994˙176 €
 EC max contribution 5˙994˙176 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) coordinator 1˙914˙531.00
2    DANMARKS TEKNISKE UNIVERSITET DK (KGS LYNGBY) participant 1˙078˙407.00
3    PHILOGEN SPA IT (SIENA) participant 726˙250.00
4    HEALTH INNOVATION VENTURES BV NL (MAASTRICHT) participant 434˙250.00
5    PT THERAGNOSTIC BV NL (MAASTRICHT) participant 312˙500.00
6    ACADEMISCH ZIEKENHUIS MAASTRICHT NL (MAASTRICHT) participant 181˙675.00
7    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 165˙050.00
8    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 165˙050.00
9    CENTRE OSCAR LAMBRET FR (LILLE) participant 115˙175.00
10    CLINIQUES UNIVERSITAIRES SAINT-LUC BE (BRUXELLES) participant 115˙175.00
11    STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS NL (AMSTERDAM) participant 115˙175.00
12    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 115˙175.00
13    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 115˙175.00
14    UNIVERSITA CATTOLICA DEL SACRO CUORE IT (MILANO) participant 115˙175.00
15    UNIVERSITAIR ZIEKENHUIS GENT BE (GENT) participant 115˙175.00
16    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 115˙175.00
17    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 95˙062.00

Map

 Project objective

IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the irradiated metastatic site(s), and the effect of the tumour-specific immunocytokine L19-IL2 (watch our animation explaining the concept at https://youtu.be/6wDE6RkrikA).

Palliative treatment is the current standard of care for patients with metastatic non small cell lung cancer (NSCLC), unless there is an actionable mutation. By using the concept of limited metastatic disease (≤10 sites, WHO 0-1: “oligo”) we aim to develop a therapy with curative intent. IMMUNOSABR will gather evidence for the clinical efficacy of our bi-modal treatment strategy in a multicentre randomised phase II study (clinicaltrials.gov no. NCT02735850) in patients with limited metastatic NSCLC.

IMMUNOSABR is complemented by two strong biomarker work packages which focus on developing an ambitious personalised biomarker strategy, to identify patients who can benefit from the novel treatment strategy. This includes promising non-invasive imaging techniques and state-of-the-art immunological monitoring approaches on tumour tissue and blood. IMMUNOSABR will spur further development of L19-IL2 as a commercial drug and translate the bi-modal treatment strategy towards clinical implementation.

 Publications

year authors and title journal last update
List of publications.
2018 Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E. van Timmeren, Cary Oberije, Wouter van Elmpt, Lioe-Fee de Geus-Oei, Johan Bussink, Philippe Lambin
18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) – A prospective externally validated study
published pages: e0192859, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0192859
PLOS ONE 13/3 2020-04-08
2018 David A. Jaffray, Shiva Das, Paula M. Jacobs, Robert Jeraj, Philippe Lambin
How Advances in Imaging Will Affect Precision Radiation Oncology
published pages: 292-298, ISSN: 0360-3016, DOI: 10.1016/j.ijrobp.2018.01.047
International Journal of Radiation Oncology*Biology*Physics 101/2 2020-04-08
2018 Ralph TH Leijenaar, Marta Bogowicz, Arthur Jochems, Frank JP Hoebers, Frederik WR Wesseling, Sophie H Huang, Biu Chan, John N Waldron, Brian O\'Sullivan, Derek Rietveld, C Rene Leemans, Ruud H Brakenhoff, Oliver Riesterer, Stephanie Tanadini-Lang, Matthias Guckenberger, Kristian Ikenberg, Philippe Lambin
Development and validation of a radiomic signature to predict HPV (p16) status from standard CT imaging: a multicenter study
published pages: 20170498, ISSN: 0007-1285, DOI: 10.1259/bjr.20170498
The British Journal of Radiology 2020-04-08
2018 Daniëlle B.P. Eekers, Esther N. Pijnappel, Olaf E.M.G. Schijns, Albert Colon, Ann Hoeben, Jaap D. Zindler, Alida A. Postma, Aswin L. Hoffmann, Philippe Lambin, Esther G.C. Troost
Evidence on the efficacy of primary radiosurgery or stereotactic radiotherapy for drug-resistant non-neoplastic focal epilepsy in adults: A systematic review
published pages: 83-92, ISSN: 1059-1311, DOI: 10.1016/j.seizure.2018.01.009
Seizure 55 2020-04-08
2018 Richard P. Baum, Harshad R. Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Mueller, Vikas Prasad, Merten Hommann, Franz C. Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter Hörsch
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.24524
Oncotarget 9/24 2020-04-08
2018 Davide Cusumano, Nicola Dinapoli, Luca Boldrini, Giuditta Chiloiro, Roberto Gatta, Carlotta Masciocchi, Jacopo Lenkowicz, Calogero Casà, Andrea Damiani, Luigi Azario, Johan Van Soest, Andre Dekker, Philippe Lambin, Marco De Spirito, Vincenzo Valentini
Fractal-based radiomic approach to predict complete pathological response after chemo-radiotherapy in rectal cancer
published pages: 286-295, ISSN: 0033-8362, DOI: 10.1007/s11547-017-0838-3
La radiologia medica 123/4 2020-04-08
2018 Seán Walsh, Erik Roelofs, Peter Kuess, Yvonka van Wijk, Ben Vanneste, Andre Dekker, Philippe Lambin, Bleddyn Jones, Dietmar Georg, Frank Verhaegen
Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability
published pages: 55, ISSN: 2072-6694, DOI: 10.3390/cancers10020055
Cancers 10/2 2020-04-08
2017 Ana Ureba, Emely Lindblom, Alexandru Dasu, Johan Uhrdin, Aniek J. G. Even, Wouter van Elmpt, Philippe Lambin, Peter Wersäll, Iuliana Toma-Dasu
Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription
published pages: 485-490, ISSN: 0284-186X, DOI: 10.1080/0284186X.2017.1400177
Acta Oncologica 57/4 2020-04-08
2018 Sena Apeke, Laurent Gaubert, Nicolas Boussion, Philippe Lambin, Dimitris Visvikis, Vincent Rodin, Pascal Redou
Multi-Scale Modeling and Oxygen Impact on Tumor Temporal Evolution: Application on Rectal Cancer During Radiotherapy
published pages: 871-880, ISSN: 0278-0062, DOI: 10.1109/TMI.2017.2771379
IEEE Transactions on Medical Imaging 37/4 2020-04-08
2018 Daniëlle B.P. Eekers, Lieke in \'t Ven, Sabine Deprez, Linda Jacobi, Erik Roelofs, Ann Hoeben, Philippe Lambin, Dirk de Ruysscher, Esther G.C. Troost
The posterior cerebellum, a new organ at risk?
published pages: 22-26, ISSN: 2405-6308, DOI: 10.1016/j.ctro.2017.11.010
Clinical and Translational Radiation Oncology 8 2020-04-08
2017 Arthur Jochems, Issam El-Naqa, Marc Kessler, Charles S. Mayo, Shruti Jolly, Martha Matuszak, Corinne Faivre-Finn, Gareth Price, Lois Holloway, Shalini Vinod, Matthew Field, Mohamed Samir Barakat, David Thwaites, Dirk de Ruysscher, Andre Dekker, Philippe Lambin
A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy
published pages: 226-230, ISSN: 0284-186X, DOI: 10.1080/0284186X.2017.1385842
Acta Oncologica 57/2 2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNOSABR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUNOSABR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More